Haemonetics (HAE) Non-Current Deferred Tax Liability (2010 - 2026)

Haemonetics has reported Non-Current Deferred Tax Liability for 17 years, with the latest figure at $38.7 million in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 34.96% year-over-year to $38.7 million in Q2 2026; TTM through Jun 2026 was $38.7 million, a 34.96% decrease from a year earlier, with the FY2026 full-year figure at $38.0 million, down 72.81% from the prior year.
• Non-Current Deferred Tax Liability was $38.7 million for Q2 2026 at Haemonetics, up from $38.0 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $149.9 million in Q1 2024, with the low at $26.1 million in Q1 2022.
• Average Non-Current Deferred Tax Liability over 5 years is $63.5 million, with a median of $58.2 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2026: Non-Current Deferred Tax Liability jumped 166.57% in 2022, then tumbled 72.81% in 2026.
• Over 5 years, Non-Current Deferred Tax Liability stood at $40.2 million in 2022, then surged by 55.03% to $62.2 million in 2023, then decreased by 1.28% to $61.5 million in 2024, then decreased by 8.9% to $56.0 million in 2025, then slumped by 30.88% to $38.7 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $38.7 million (Q2 2026), $38.0 million (Q1 2026), and $56.0 million (Q4 2025), per Business Quant data.